As of early 2021, the FDA has approved four secondgeneration antiandrogen mediations: Zytiga (abiraterone acetate), Xtandi (enzalutamide), Erleada (apalutamide), and Nubeqa (darolutamide). Here, Alex asks medical oncologist Mark Scholz, MD, how these medications work and how they compare to one another, especially regarding side effects.

0:05 How exactly do secondgeneration antiandrogens treat metastatic lesions?

1:33 What are the possible side effects of the four secondgeneration antiandrogens? How do they compare?

3:06 Are any of the four secondgeneration antiandrogens more appropriate than the others for men with heart problems?

3:56 What are some ways to mitigate the side effects of secondgeneration antiandrogen medications?

5:01 How do secondgeneration hormone therapies tend to affect PSA?

Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org

To learn more about prostate cancer visit http://www.pcri.org

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) notforprofit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive betterindividualized care. Feel free to explore our website or call our free helpline at 1 (800) 6417274 with any questions that you have. Our Federal Tax ID # is 954617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #Prostate #MarkScholzMD